These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30221197)

  • 21. Development of an Emergency Department-Based Intervention to Expand Access to Medications for Opioid Use Disorder in a Medicaid Nonexpansion Setting: Protocol for Engagement and Community Collaboration.
    Walter LA; Li L; Rodgers JB; Hess JJ; Skains RM; Delaney MC; Booth J; Hess EP
    JMIR Res Protoc; 2021 Apr; 10(4):e18734. PubMed ID: 33913818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabis Use and Nonfatal Opioid Overdose among Patients Enrolled in Methadone Maintenance Treatment.
    Bryson WC; Morasco BJ; Cotton BP; Thielke SM
    Subst Use Misuse; 2021; 56(5):697-703. PubMed ID: 33749499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the Neuroimmune System a Therapeutic Target for Opioid Use Disorder? A Systematic Review.
    Toloff K; Woodcock EA
    Med Res Arch; 2022 Aug; 10(8):. PubMed ID: 37744743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
    Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
    J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior.
    Mitchell P; Samsel S; Curtin KM; Price A; Turner D; Tramp R; Hudnall M; Parton J; Lewis D
    Soc Sci Med; 2022 Jun; 302():114992. PubMed ID: 35512612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
    Felix C; Sharfstein JM; Olsen Y
    J Am Geriatr Soc; 2020 Mar; 68(3):637-640. PubMed ID: 31825528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid use disorder treatment for people experiencing homelessness: A scoping review.
    McLaughlin MF; Li R; Carrero ND; Bain PA; Chatterjee A
    Drug Alcohol Depend; 2021 Jul; 224():108717. PubMed ID: 33985863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder.
    Le K; Le KDR; Nguyen J; Hua J; Munday S
    Pain Ther; 2024 Jun; 13(3):435-455. PubMed ID: 38676910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
    Huo S; Heil J; Salzman MS; Carroll G; Haroz R
    J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 33. Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice.
    Kakko J; Alho H; Baldacchino A; Molina R; Nava FA; Shaya G
    Front Psychiatry; 2019; 10():592. PubMed ID: 31543832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.
    Gregory HM; Hill VM; Parker RW
    Cureus; 2021 Nov; 13(11):e19870. PubMed ID: 34976492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
    Butler SF; Oyedele NK; Dailey Govoni T; Green JL
    JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder.
    Maremmani I; Dematteis M; Gorzelanczyk EJ; Mugelli A; Walcher S; Torrens M
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
    Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B
    J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274
    [No Abstract]   [Full Text] [Related]  

  • 38. Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder.
    Reed MK; Murali V; Sarpoulaki N; Zavodnick JH; Hom JK; Rising KL
    Drug Alcohol Depend Rep; 2022 Dec; 5():100106. PubMed ID: 36844165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a cascade of care for opioid use disorder among individuals in jail.
    Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
    J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.